Document Management Audit Readiness
Ensure your document management system is inspection-ready across all GMP areas
Overview
What's Inside
Document management failures are among the most frequently cited observations in FDA inspections. From incomplete SOPs and poor version control to missing training records and GDP violations, documentation issues signal systemic weaknesses that investigators use to question overall site control. A robust document management system is foundational to every other quality subsystem.
This 17-page checklist provides a structured self-assessment across eight critical domains: SOP development, review, and version control; controlled document issuance and secure storage; training implementation and competency evaluation; QA oversight and internal audit readiness; Good Documentation Practices and data integrity; retention, archiving, and retrieval; manufacturing and QC record management; and policy and governance compliance.
Each section contains Yes/No/NA audit questions mapped to real inspection focus areas, covering both paper-based and electronic document management systems (EDMS). Use it to identify gaps in your document lifecycle, ensure GDP compliance, and verify that your records can withstand regulatory scrutiny from initial creation through archiving and retrieval.
Why It Matters
FDA investigators often start with documentation — if your records are incomplete, inconsistent, or inaccessible, every other system comes under suspicion. GDP violations, missing training records, uncontrolled document issuance, and inadequate retention practices are reliable predictors of broader compliance failures. This checklist ensures your documentation foundation is solid before inspectors arrive.
What's Covered
Sections in this checklist
- SOP development, review, version control, and compliance
- Controlled document issuance, tracking, and EDMS management
- Document security, storage, and digital backup systems
- Training implementation, competency evaluation, and oversight
- QA oversight, review cycles, and internal audit readiness
- Good Documentation Practices (GDP) and data integrity controls
- Retention, archiving, retrieval, and traceability procedures
- Manufacturing batch records and QC laboratory record management
- Policy governance alignment and regulatory harmonisation
Who It's For
Target roles
Regulatory Basis
21 CFR 211.186, 21 CFR 211.188, 21 CFR Part 11, ICH Q10, EU GMP Annex 11, WHO TRS 996
Download Document Management Audit Readiness
Enter your details once to unlock all Audit Hub resources. All future downloads are instant.
Next step
Close the gaps this checklist looks for
This checklist maps what FDA investigators expect of a document management system. Leucine Documents is how pharmaceutical manufacturers run it in practice: controlled SOPs and records with validated version control, risk-tiered approval routing, a non-defeatable 21 CFR Part 11 audit trail, and training triggered automatically at effectivity, kept current across every site.
Related Checklists
Complaint Management Audit Readiness
End-to-end audit readiness checklist for pharmaceutical complaint management systems, covering complaint investigation thoroughness, root cause analysis, retain sample testing, CAPA linkage, and trending analysis aligned with FDA 483 focus areas.
CAPA Management Audit Readiness
Audit readiness checklist for CAPA systems covering initiation timeliness, root cause analysis quality, effectiveness checks, recurrence prevention, and management review integration — built from real FDA 483 observation patterns.
Quality Risk Management Audit Readiness (ICH Q9)
Comprehensive 100-point QRM audit checklist spanning all six FDA systems plus documentation, training, complaint management, and continuous improvement — structured as Yes/No/NA self-assessment questions aligned with ICH Q9 and ICH Q10.
Leucine is the first AI-native platform built for pharmaceutical manufacturing. It unifies quality management, regulatory compliance, and production operations into one intelligent system that powers your entire drug manufacturing lifecycle from raw materials to patient delivery.
